{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:21:49Z","timestamp":1792801309230,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40263-014-0155-5","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T15:17:28Z","timestamp":1394637448000},"page":"373-387","source":"Crossref","is-referenced-by-count":78,"title":["Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"28","author":[{"given":"Celeste B.","family":"Burness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"issue":"9648","key":"155_CR1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"issue":"4","key":"155_CR2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1172\/JCI58649","volume":"122","author":"A Nylander","year":"2012","unstructured":"Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180\u20138.","journal-title":"J Clin Invest"},{"issue":"17","key":"155_CR3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2165\/0003495-200868170-00004","volume":"68","author":"T Menge","year":"2008","unstructured":"Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445\u201368.","journal-title":"Drugs"},{"key":"155_CR4","unstructured":"World Health Organization. Atlas: multiple sclerosis resources in the world; 2008. http:\/\/www.who.int\/mental_health\/neurology\/Atlas_MS_WEB.pdf . Accessed 14 Feb 2014."},{"issue":"Pt 1","key":"155_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133\u201346.","journal-title":"Brain"},{"issue":"7","key":"155_CR6","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awr128","volume":"134","author":"L Haider","year":"2011","unstructured":"Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134(7):1914\u201324.","journal-title":"Brain"},{"issue":"9","key":"155_CR7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","volume":"354","author":"EM Frohman","year":"2006","unstructured":"Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942\u201355.","journal-title":"N Engl J Med"},{"key":"155_CR8","first-page":"101","volume":"5","author":"N Girouard","year":"2011","unstructured":"Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence. 2011;5:101\u20138.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"155_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169\u201378.","journal-title":"Neurology"},{"key":"155_CR10","unstructured":"National Institute for Clinical Excellence. Multiple sclerosis: national clinical guideline for diagnosis and management; 2003. http:\/\/www.nice.org.uk\/nicemedia\/live\/10930\/46699\/46699.pdf . Accessed 14 Feb 2014."},{"issue":"10","key":"155_CR11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00415-008-0061-1","volume":"255","author":"H Wiendl","year":"2008","unstructured":"Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449\u201363.","journal-title":"J Neurol"},{"issue":"1","key":"155_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1331.2006.01147.x","volume":"13","author":"D Karussis","year":"2006","unstructured":"Karussis D, Biermann LD, Bohlega S, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol. 2006;13(1):61\u201371.","journal-title":"Eur J Neurol"},{"issue":"6","key":"155_CR13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.nrl.2013.01.009","volume":"28","author":"A Garc\u00eda-Merino","year":"2013","unstructured":"Garc\u00eda-Merino A, Fernandez O, Montalban X. Consensus statement on medication use in multiple sclerosis by the Spanish Society of Neurology\u2019s study group for demyelinating diseases. Neurologia. 2013;28(6):375\u20138.","journal-title":"Neurologia"},{"key":"155_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/DHPS.S28822","volume":"5","author":"J Thone","year":"2013","unstructured":"Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf. 2013;5:37\u201347.","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"155_CR15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/11539820-000000000-00000","volume":"25","author":"R Gold","year":"2011","unstructured":"Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs. 2011;25(1):37\u201352.","journal-title":"CNS Drugs"},{"issue":"8","key":"155_CR16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40263-013-0080-z","volume":"27","author":"J Oh","year":"2013","unstructured":"Oh J, O\u2019Connor PW. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs. 2013;27(8):591\u2013609.","journal-title":"CNS Drugs"},{"key":"155_CR17","unstructured":"Biogen I. Biogen Idecs TECFIDERA (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis [media release]; 2013. http:\/\/www.biogenidec.com ."},{"key":"155_CR18","unstructured":"Biogen Idec Canada. Health Canada approves TECFIDERA\u2122 as a first-line oral treatment for multiple sclerosis [media release]; 2013. http:\/\/www.newswire.ca\/en\/story\/1142785\/health-canada-approves-tecfideratm-as-a-first-line-oral-treatment-for-multiple-sclerosis ."},{"key":"155_CR19","unstructured":"Biogen Idec Inc. Tecfidera (dimethyl fumarate): US prescribing information; 2013. http:\/\/www.tecfidera.com\/pdfs\/full-prescribing-information.pdf . Accessed 14 Feb 2014."},{"key":"155_CR20","unstructured":"Biogen Idec Ltd. Tecfidera 240\u00a0mg gastro-resistant hard capsules: summary of product characteristics; 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/28592\/SPC\/Tecfidera+240mg+gastro-resistant+hard+capsules\/ . Accessed 14 Feb 2014."},{"key":"155_CR21","unstructured":"Biogen Idec Australia Pty Ltd. TECFIDERA (dimethyl fumarate [DMF]): product information; 2013. http:\/\/www.tga.gov.au\/pdf\/auspar\/auspar-dimethyl-fumarate-131022-pi.pdf . Accessed 14 Feb 2014."},{"issue":"1","key":"155_CR22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","volume":"341","author":"RH Scannevin","year":"2012","unstructured":"Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341(1):274\u201384.","journal-title":"J Pharmacol Exp Ther"},{"key":"155_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1742-2094-9-163","volume":"9","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"155_CR24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0033-1343796","volume":"33","author":"JT Phillips","year":"2013","unstructured":"Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol. 2013;33(1):56\u201365.","journal-title":"Semin Neurol"},{"issue":"3","key":"155_CR25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(3):678\u201392.","journal-title":"Brain"},{"issue":"1","key":"155_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","volume":"145","author":"S Schilling","year":"2006","unstructured":"Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145(1):101\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"155_CR27","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bcp.2008.07.017","volume":"76","author":"W Li","year":"2008","unstructured":"Li W, Khor TO, Xu C, et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol. 2008;76(11):1485\u20139.","journal-title":"Biochem Pharmacol"},{"issue":"33","key":"155_CR28","doi-asserted-by":"crossref","first-page":"28017","DOI":"10.1074\/jbc.M112.383380","volume":"287","author":"H Peng","year":"2012","unstructured":"Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1\/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287(33):28017\u201326.","journal-title":"J Biol Chem"},{"key":"155_CR29","doi-asserted-by":"crossref","unstructured":"Schulze-Topphoff U, Varrin-Doyer M, Pekarek R, et al. Dimethyl fumarate utilizes Nrf2-independent and Nrf2-dependent pathways for immune modulation [abstract no. P565]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen.","DOI":"10.1212\/WNL.82.10_supplement.S53.006"},{"issue":"2","key":"155_CR30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/AN20100033","volume":"3","author":"SX Lin","year":"2011","unstructured":"Lin SX, Lisi L, Dello Russo C, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011;3(2):75\u201384.","journal-title":"ASN Neuro"},{"issue":"11","key":"155_CR31","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","volume":"208","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291\u2013303.","journal-title":"J Exp Med"},{"key":"155_CR32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-2094-7-30","volume":"7","author":"H Wilms","year":"2010","unstructured":"Wilms H, Sievers J, Rickert U, et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010;7:30.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"155_CR33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2006.01292.x","volume":"13","author":"S Schimrigk","year":"2006","unstructured":"Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604\u201310.","journal-title":"Eur J Neurol"},{"key":"155_CR34","unstructured":"Biogen Idec Canada Inc. Tecfidera (dimethyl fumarate delayed-release capsules 120\u00a0mg): Canadian product monograph; 2013. http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/dispatch-repartition.do?lang=eng . Accessed 14 Feb 2014."},{"issue":"6","key":"155_CR35","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","volume":"121","author":"F Treumer","year":"2003","unstructured":"Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121(6):1383\u20138.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"155_CR36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"12","key":"155_CR37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"8","key":"155_CR38","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","volume":"120","author":"J Hanson","year":"2010","unstructured":"Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910\u20139.","journal-title":"J Clin Invest"},{"issue":"3","key":"155_CR39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/fnl.13.11","volume":"8","author":"J Horssen Van","year":"2013","unstructured":"Van Horssen J, De Vries HE. Dimethyl fumarate: a novel oral front-line therapy for multiple sclerosis treatment. Future Neurol. 2013;8(3):247\u201354.","journal-title":"Future Neurol"},{"key":"155_CR40","unstructured":"Dawson KT, Nestorov I, Manchanda R, et al. Bioequivalence of BG-12 administered as a single 240\u00a0mg capsule and two 120\u00a0mg capsules: findings from a randomised, two-period crossover study [abstract no. P 913]. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10\u201313 Oct 2012; Lyon."},{"issue":"10","key":"155_CR41","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.clinthera.2013.08.009","volume":"35","author":"S Sheikh","year":"2013","unstructured":"Sheikh S, Nestorov I, Russell H, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013;35(10):1582\u201394.","journal-title":"Clin Ther"},{"key":"155_CR42","unstructured":"Woodworth J, Zhao Z, Stecher S. Pharmacokinetics of oral BG-12 alone compared with BG-12 and interferon beta-1a or glatiramer acetate administered together, studied in healthy volunteers [abstract no. P04.207]. 62nd Annual Meeting of the American Academy of Neurology; 10\u201317 Apr 2010; Toronto."},{"key":"155_CR43","doi-asserted-by":"crossref","unstructured":"Kappos L, Giovannoni G, Gold R, et al. Timecourse of treatment effects of BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis [abstract no. DX40 plus poster]. Fifth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis; 16\u201323 Mar 2013; Orlando, FL.","DOI":"10.1212\/WNL.80.7_supplement.S41.005"},{"key":"155_CR44","doi-asserted-by":"crossref","unstructured":"Fox R, Miller D, Arnold D, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. P07.097]. 65th Annual Meeting of the American Academy of Neurology; 16\u201323 Mar 2013; San Diego, CA.","DOI":"10.1016\/j.jns.2013.07.1345"},{"key":"155_CR45","doi-asserted-by":"crossref","unstructured":"Bar-Or A, Fox RJ, Gold R, et al. Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract]. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10\u201313 Oct 2012; Lyon.","DOI":"10.1016\/j.jval.2013.03.481"},{"key":"155_CR46","doi-asserted-by":"crossref","unstructured":"Kita M, Fox R, Arnold D, et al. Clinical and neuroradiologic efficacy of BG-12 (dimethyl fumarate) in US patients with relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. P07.091]. 65th Annual Meeting of the American Academy of Neurology; 16\u201324 Mar 2013; San Diego, CA.","DOI":"10.1016\/j.jval.2013.03.481"},{"key":"155_CR47","doi-asserted-by":"crossref","unstructured":"Hutchinson M, Fox RJ, Bar-Or A, et al. Efficacy of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis in patients from Europe: an integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen.","DOI":"10.1212\/WNL.80.7_supplement.P07.128"},{"key":"155_CR48","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Gold R, Fox R, et al. Relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations: an integrated analysis of the BG-12 (dimethyl fumarate) phase 3 studies [abstract no. P07.121]. 65th Annual Meeting of the American Academy of Neurology; 16\u201323 Mar 2013; San Diego, CA.","DOI":"10.1016\/j.jval.2013.03.479"},{"key":"155_CR49","doi-asserted-by":"crossref","unstructured":"Bar-Or A, Arnold D, Gold R, et al. Effects of oral BG-12 (dimethyl fumarate) on magnetic resonance imaging (MRI) outcomes in relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase 3 define and confirm studies [abstract]. 65th American Academy of Neurology Annual Meeting; 16\u201323 Mar 2013; San Diego, CA.","DOI":"10.1016\/j.jval.2013.03.481"},{"key":"155_CR50","unstructured":"Arnold D, Gold R, Kappos L, et al. Effect of BG-12 on brain atrophy and lesions volume: MRI results from the define study during first and second year of treatment [abstract no. S11.003]. 64th American Academy of Neurology Annual Meeting; 21\u201328 Apr 2012; New Orleans, LA."},{"key":"155_CR51","unstructured":"Miller DH, Hutchinson M, Fox RJ, et al. Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study [abstract no. P 464 plus poster]. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10\u201313 Oct 2012; Lyon."},{"key":"155_CR52","unstructured":"Arnold D, Gold R, Kappos L, et al. Effects of BG-12 on magnetization transfer ratio in whole brain and normal-appearing brain tissue: findings from the DEFINE study [abstract no. S11.004]. 64th American Academy of Neurology Annual Meeting; 21\u201328 Apr 2012; New Orleans, LA."},{"key":"155_CR53","doi-asserted-by":"crossref","unstructured":"Kita M, Fox R, Gold R, et al. Effects of BG-12 (dimethyl fumarate) on quality of life in patients with relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. P07.092]. 65th Annual Meeting of the American Academy of Neurology; 16\u201323 Mar 2013; San Diego, CA.","DOI":"10.1016\/j.jval.2013.03.481"},{"key":"155_CR54","unstructured":"Kappos L, Gold R, Arnold D, et al. BG-12 effects on patient-reported outcomes in relapsing-remitting multiple sclerosis: results from the DEFINE study [abstract no. P1071]. Mult Scler. 2011;17(10 Suppl):S488\u20139."},{"key":"155_CR55","unstructured":"Miller DH, Fox RJ, Gold R, et al. Four-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE [abstract no. P538 plus poster]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR56","unstructured":"Gold R, Phillips JT, Bar-Or A, et al. Four-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies [abstract no. P1004 plus poster]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR57","unstructured":"Kita M, Fox RJ, Gold R, et al. Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study [abstract no. P1127 plus poster]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR58","unstructured":"Center for Drug Evaluation and Research. Medical Review(s) application number 204063Orig1s000; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204063Orig1s000MedR.pdf . Accessed 14 Feb 2014."},{"issue":"9","key":"155_CR59","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s00415-013-6954-7","volume":"260","author":"A Bar-Or","year":"2013","unstructured":"Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9):2297\u2013305.","journal-title":"J Neurol"},{"issue":"9","key":"155_CR60","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s00415-013-6968-1","volume":"260","author":"M Hutchinson","year":"2013","unstructured":"Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260(9):2286\u201396.","journal-title":"J Neurol"},{"key":"155_CR61","doi-asserted-by":"crossref","unstructured":"Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study. Mult Scler. 2014;20(2):243\u201352.","DOI":"10.1177\/1352458513507817"},{"key":"155_CR62","doi-asserted-by":"crossref","unstructured":"Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler. 2014;20(2):253\u20137.","DOI":"10.1177\/1352458513507818"},{"key":"155_CR63","unstructured":"O\u2019Gorman J, Russell H, Li J, et al. Effect of aspirin pretreatment or slow dose titration on the incidence and severity of flushing and gastrointestinal events associated with BG-12 (dimethyl fumatate) [abstract no. P651]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR64","unstructured":"Selmaj K, Gold R, Fox RJ, et al. Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate in the phase 3 DEFINE and CONFIRM trials [abstract no. P537]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR65","unstructured":"Fox RJ, Gold R, Phillips JT, et al. Lymphocyte count reductions in relapsing remitting multiple sclerosis (RRMS) patients treatmented with oral BG-12 (dimethy fumarate): integrated analysis of the placebo-controlled studies [abstract no. P1018 plus poster]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR66","doi-asserted-by":"crossref","unstructured":"Gold R, Phillips JT, Havrdova E, et al. Oral BG-12 (dimethyl fumarate) and pregnancy: preclinical studies and pregnancy outcomes reported during the clinical development programme [abstract no. P991]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen.","DOI":"10.1016\/j.jns.2013.07.1388"},{"key":"155_CR67","doi-asserted-by":"crossref","unstructured":"Phillips JT, Fox RJ, Selmaj K, et al. Safety profile of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis: long-term interim results from the ENDORSE extension study [abstract no. P996 plus poster]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen.","DOI":"10.1212\/WNL.82.10_supplement.P2.200"},{"issue":"17","key":"155_CR68","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"U Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657\u20138.","journal-title":"N Engl J Med"},{"issue":"17","key":"155_CR69","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","volume":"368","author":"BW Oosten Van","year":"2013","unstructured":"Van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658\u20139.","journal-title":"N Engl J Med"},{"issue":"17","key":"155_CR70","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","volume":"368","author":"MT Sweetser","year":"2013","unstructured":"Sweetser MT, Dawson KT, Bozic C. Manufacturer\u2019s response to case reports of PML. N Engl J Med. 2013;368(17):1659\u201361.","journal-title":"N Engl J Med"},{"key":"155_CR71","unstructured":"Biogen Idec. Tecfidera (dimethyl fumarate) pregnancy exposure registry (TEC-GISTRY) [ClinicalTrials.gov identifier NCT01911767]. US National Institutes of Health, ClinicalTrials.gov; 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01911767 . Accessed 14 Feb 2014."},{"key":"155_CR72","unstructured":"Biogen Idec Ltd. Tecfidera 120\u00a0mg gastro-resistant hard capsules: summary of product characteristics; 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/28593\/SPC\/Tecfidera+120mg+gastro-resistant+hard+capsules\/ . Accessed 14 Feb 2014."},{"issue":"1","key":"155_CR73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/brain\/121.1.3","volume":"121","author":"DH Miller","year":"1998","unstructured":"Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121(1):3\u201324.","journal-title":"Brain"},{"key":"155_CR74","unstructured":"Phillips JT, Hutchinson M, Fox R, et al. Management strategies for flushing and gastrointestinal events associated with BG-12 (dimethyl fumarate): expert panel recommendations [abstract no. P549]. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis; 2\u20135 Oct 2013; Copenhagen."},{"key":"155_CR75","unstructured":"Biogen Idec. BG00012 phase 2 combination study in subjects with multiple sclerosis (EXPLORE) [ClinicalTrials.gov identifier NCT01156311]. US National Institutes of Health, ClinicalTrials.gov; 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01156311 . Accessed 14 Feb 2014."},{"key":"155_CR76","doi-asserted-by":"crossref","unstructured":"Su W, Walker A, Sarda S, et al. The cost effectiveness of BG-12 (dimethyl fumarate) for the treatment of relapsing-remitting multiple sclerosis in Canada [abstract no. PND28]. ISPOR 16th Annual European Congress; 2\u20136 Nov 2013; Dublin.","DOI":"10.1016\/j.jval.2013.08.1826"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0155-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0155-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0155-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:39:55Z","timestamp":1716593995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0155-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0155-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]}}}